论文部分内容阅读
目的构建吡柔比星脂质体,提高吡柔比星的生物利用度和抑瘤作用,降低其毒副作用。方法采用薄膜水化法制备吡柔比星脂质体,并测定其包封率和物理性状。构建乳腺癌细胞U14的荷瘤裸鼠模型,分别尾静脉注射吡柔比星裸药及吡柔比星脂质体,分析其抑瘤作用。结果薄膜水化法制备的吡柔比星脂质体平均粒径(140.9±2.36)nm,多分散系数为(0.203±0.01),Zeta电位为-(14.2±2.64)m V,包封率为(75.1±3.5)%,并且可以缓释吡柔比星;吡柔比星脂质体组抑瘤率(75.1±8.6)%高于吡柔比星裸药组(64.9±12.2)%。结论吡柔比星脂质体是很有潜力的抗肿瘤纳米药物。
Objective To construct the pirarubicin liposomes and improve the bioavailability and anti-tumor effect of pirarubicin and reduce its toxicity. Methods Pirarubicin liposomes were prepared by membrane hydration method, and their entrapment efficiency and physical properties were determined. The tumor-bearing nude mouse model of breast cancer cell line U14 was constructed, and the pirarubicin and pirarubicin liposomes were respectively injected into the caudal vein to analyze its anti-tumor effect. Results The average diameter of pirarubicin liposomes prepared by the membrane hydration method was (140.9 ± 2.36) nm, the polydispersity index was (0.203 ± 0.01) and the zeta potential was - (14.2 ± 2.64) m V, the entrapment efficiency was (75.1 ± 3.5)%, and the sustained release of pirarubicin; Pirarubicin liposome inhibition rate (75.1 ± 8.6)% higher than the pirarubicin group (64.9 ± 12.2)%. Conclusion Pirarubicin liposomes are promising antitumor nanomedicine.